Ownership and insider activity for AC Immune S.A. (ACIU): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically.
Price
| Price | $2.65 |
| Market Cap | $270M |
| Exchange | NASDAQ |
| Country | CH |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-11 | Twyman Roy Ervin | A-Award | 16,568 | |
| 2026-06-11 | Twyman Roy Ervin | A-Award | 38,889 | $102K |
| 2026-06-11 | AGUIAR-LUCANDER RENEE | A-Award | 16,568 | |
| 2026-06-11 | AGUIAR-LUCANDER RENEE | A-Award | 38,889 | $102K |
| 2026-06-11 | Zuegel Martin | A-Award | 77,778 | $204K |
| 2026-06-11 | Zuegel Martin | A-Award | 33,136 | |
| 2026-06-11 | Buetler Monika | A-Award | 17,751 | |
| 2026-06-11 | Buetler Monika | A-Award | 41,667 | $109K |
| 2026-06-11 | June Carl Howard | A-Award | 16,568 | |
| 2026-06-11 | June Carl Howard | A-Award | 38,889 | $102K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $152.2M | $124.4M | $156.5M | $193.6M | $160.9M | $82.2M | $31.6M | $78.5M | $36.3M | $26.8M |
| Short-term Investments | 0 | 0 | $30.0M | $95.0M | $65.0M | $116.0M | $91.0M | $24.6M | $129.2M | $64.7M |
| Receivables | $1.4M | $3.7M | $4.1M | $1.4M | $1.6M | $975000 | $408000 | $15.0M | $1.1M | $1.3M |
| Inventory | $389000 | -$1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $154.9M | $129.5M | $192.9M | $292.8M | $231.8M | $202.6M | $128.1M | $125.2M | $172.0M | $96.8M |
| Property, Plant & Equipment | $1.1M | $2.4M | $3.3M | $6.2M | $6.6M | $8.0M | $7.1M | $6.9M | $8.1M | $6.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $50.4M | $50.4M | $50.4M | $50.4M | $50.5M |
| Total Assets | $156.1M | $132.0M | $196.6M | $299.2M | $238.7M | $261.4M | $185.9M | $182.8M | $230.9M | $154.4M |
| Accounts Payable | $4.0M | $1.1M | $2.0M | $142000 | $2.2M | $2.0M | $929000 | $1.7M | $2.7M | $2.1M |
| Short-term Debt | 0 | 0 | $332000 | $652000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $9.9M | $9.8M | $13.1M | $17.5M | $14.0M | $20.0M | $11.5M | $13.6M | $100.8M | $94.8M |
| Long-term Debt | 0 | $494000 | $186000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $13.7M | $15.2M | $18.9M | $26.8M | $23.3M | $29.5M | $16.9M | $22.2M | $118.6M | $109.5M |
| Retained Earnings | -$46.9M | -$72.6M | -$121.9M | -$75.5M | -$132.8M | -$200.9M | -$264.0M | -$316.2M | -$368.2M | -$439.5M |
| Total Equity | $142.4M | $116.8M | $177.6M | $272.4M | $215.5M | $232.0M | $169.0M | $160.6M | $112.3M | $44.9M |
| Total Debt | 0 | $395000 | $518000 | $2.9M | $2.2M | $2.9M | $2.8M | $3.5M | $5.4M | $4.5M |
| Net Debt | -$152.2M | -$124.0M | -$185.9M | -$285.7M | -$223.7M | -$195.3M | -$119.8M | -$99.6M | -$160.1M | -$86.9M |
| Working Capital | $145.0M | $119.8M | $179.8M | $275.3M | $217.7M | $182.6M | $116.6M | $111.6M | $71.2M | $2.0M |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 0.93 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.04 |
Profitability
| Return on Equity | -99.17% |
| Return on Invested Capital | -86.61% |
| Return on Assets | -28.70% |
| Gross Margin | 100.00% |
| Operating Margin | -252.25% |
| Net Margin | -246.49% |
Related companies: ALDX · AMRN · ANNX · ANRO · CLLS · CTNM · DRTS
Explore sector: Healthcare · Biotechnology
More sections of ACIU: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks